Immunization Action Coalition • (651) 647‐9009 • www.immunize.org • www.immunize.org/catg.d/S8005.pdf • Item #S8005 (8/19) 1 Adolescent Immunization Update and the 16-year-old Platform Sharon G. Humiston, MD, MPH Associate Director for Research Immunization Action Coalition Deborah L. Wexler, MD Executive Director Immunization Action Coalition August 2019・Item #S8005 Overview • 16-year-old adolescent immunization platform • Adolescent immunization rates • Vaccination recommendations & updates • Wrap up Immunization Platforms Benefits of Immunization Platforms • Ensure we give our patients all their recommended vaccines, and if not done earlier, catch them up on any vaccines they may have missed • Using the 16-year-old platform – Helps ensure that vaccines recommended at age 16 are given while the patients are still covered by public or private insurance – Benefit of creating the opportunity to provide • Developmentally targeted care and • Anticipatory guidance 5 Auslander B et al. J Adolescent Health 2017;60:475-6. “Dear Colleague” or “Call to Action” Letter Signed by: • AAFP • AAP • ACHA • ACOG • APhA • IAC • SAHM 1 2 3 4 5 6
17
Embed
Immunization Platforms · Immunization Action Coalition • (651) 647‐9009 • • • Item#S8005 (8/19) 7 37 W C A Y There is currently no ...
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Estimated coverage with selected vaccines and doses among adolescentsage 13–17 years, by survey year and ACIP recommendation—National Immunization Survey-Teen, United States, 2006–2017
26
Estimated coverage with selected vaccines and doses among adolescentsage 13–17 years, by survey year and ACIP recommendation—National Immunization Survey-Teen, United States, 2006–2017
27
Tdap
Estimated coverage with selected vaccines and doses among adolescentsage 13–17 years, by survey year and ACIP recommendation—National Immunization Survey-Teen, United States, 2006–2017
28
Tdap
HPV dose 1
Estimated coverage with selected vaccines and doses among adolescentsage 13–17 years, by survey year and ACIP recommendation—National Immunization Survey-Teen, United States, 2006–2017
29
Tdap
HPV dose 2
HPV dose 1
Estimated coverage with selected vaccines and doses among adolescentsage 13–17 years, by survey year and ACIP recommendation—National Immunization Survey-Teen, United States, 2006–2017
Estimated coverage with selected vaccines and doses among adolescentsage 13–17 years, by survey year and ACIP recommendation—National Immunization Survey-Teen, United States, 2006–2017
31
MenACWYdose 1
MenACWYdose 2
MeningococcalDisease and Vaccines
Meningococcal Disease
Relatively rare – In 2017, there were ~350 cases of meningococcal disease reported (all serogroups)
Large toll
• Invasive meningococcal disease: 10%–15% patients die, even with antibiotic treatment
• Meningococcemia: up to 40% die
• Among survivors: Up to _____ sustain lifelong disability such as arm or leg amputation, hearing loss, or neurologic damage
33 MMWR 2013;62(RR-2):15; MMWR 2015;64:608-12
Meningococcal Disease
Relatively rare – In 2017, there were ~350 cases of meningococcal disease reported (all serogroups)
Large toll
• Invasive meningococcal disease: 10%–15% patients die, even with antibiotic treatment
• Meningococcemia: up to 40% die
• Among survivors: Up to _____ sustain lifelong disability such as arm or leg amputation, hearing loss, or neurologic damage
34
20%
MMWR 2013;62(RR-2):15; MMWR 2015;64:608-12
Two Types of Meningococcal Vaccines
• Meningococcal Serogroup ACWY Vaccines (MenACWY)
– Available since 2005
– ACIP routine recommendations• In 2005 – Routinely recommended at age 11−12
• In 2010 – Booster dose recommended at age 16
35 MMWR 2013;62(RR-2):15; MMWR 2015;64:608-12
Two Types of Meningococcal Vaccines
• Meningococcal Serogroup ACWY Vaccines (MenACWY)
– Available since 2005
– ACIP routine recommendations• In 2005 – Routinely recommended at age 11−12
• In 2010 – Booster dose recommended at age 16
36
• Meningococcal Serogroup B Vaccines (MenB)
– Available since late 2014
– ACIP routine recommendations• In 2015 – Routinely recommended for people at increased risk
age >10 years
• Later in 2015 – “May be given” to healthy persons 16 to 23 years of age, preferred at 16−18
• Routine (formerly Category A) for persons age 10 or older at high risk:– Functional or anatomic asplenia
– Persistent complement component deficiency, including people taking eculizumab (Soliris)
– At risk during an outbreak caused by a vaccine serogroup, such as on college campuses
– Microbiologists who work with meningococcus bacteria in a laboratory
• Shared Clinical Decision-Making (formerly Category B)
– ACIP recommends a MenB primary series for individuals aged 16–23 years based on shared clinical decision-making
– Preferred age of vaccination of 16 through 18 years
CDC will publish an updated statement
68
• Will include new “shared clinical decision-making” language
• Will incorporate all existing ACIP recommendations for MenACWY and MenB vaccines into a single document
• Will include the new booster recommendations for high risk individuals
Watch for an announcement in IAC Express
69
Routine Recommendations
Risk-based Recommendations
www.immunize.org/catg.d/p2035.pdf
MenB Vaccines ARE Covered by VFC & ACA
70
Vaccines are included in the Vaccines For Children (VFC) program and the Affordable Care Act (ACA) if there is either kind of ACIP recommendation for them:
1. Everything that can go wrong has gone wrong, so check the immunization record and give the missing vaccines
92
2. Hepatitis B vaccine is often missed!
3. Hepatitis A deserves your attention, too.
– Catch-up vaccination of children and adolescents
– Persons with HIV infection
– An update on hepatitis A vaccination will be published
93
WebinarWrap-up
www.immunize.org/catg.d/u6005.pdf
Summary of today’s webinar
• Establish a 16-year-old visit in your office to make sure these patients receive the vaccines they need
94
Summary of today’s webinar
• Establish a 16-year-old visit in your office to make sure these patients receive the vaccines they need
• Practices should follow the ACIP immunization schedule and help families adhere to it
95
Summary of today’s webinar
• Establish a 16-year-old visit in your office to make sure these patients receive the vaccines they need
• Practices should follow the ACIP immunization schedule and help families adhere to it
• The 11–12 and 16-year-old platforms provide opportunities to review and complete all needed vaccination while the vaccines are covered by public or private insurance
• Establish a 16-year-old visit in your office to make sure these patients receive the vaccines they need
• Practices should follow the ACIP immunization schedule and help families adhere to it
• The 11–12 and 16-year-old platforms provide opportunities to review and complete all needed vaccination while the vaccines are covered by public or private insurance
• Develop strategies using tools discussed today to improve adolescent vaccination rates in your healthcare setting
97
Immunization Action Coalition Resources
98
Subscribe to IAC Express, IAC’s weekly e-newsletter
• www.immunize.org/subscribe
Websites
• www.immunize.org (for HCP)
• www.Give2MenACWY.org (for HCP)
• www.vaccineinformation.org (for the public)
Acknowledgements
William L. Atkinson, MD, MPH
Laurel Wood, MPACoordinator for Public Health
This Photo by Unknown Author is licensed under CC BY-NC-ND
Thank you!
This Photo by Unknown Author is licensed under CC BY-NC-ND